Dysregulated Arginine Metabolism, Hemolysis-Associated Pulmonary Hypertension and Mortality in Sickle Cell Disease

University of Pittsburgh, Pittsburgh, Pennsylvania, United States
JAMA The Journal of the American Medical Association (Impact Factor: 35.29). 07/2005; 294(1):81-90. DOI: 10.1001/jama.294.1.81
Source: PubMed


Sickle cell disease is characterized by a state of nitric oxide resistance and limited bioavailability of l-arginine, the substrate for nitric oxide synthesis. We hypothesized that increased arginase activity and dysregulated arginine metabolism contribute to endothelial dysfunction, pulmonary hypertension, and patient outcomes.
To explore the role of arginase in sickle cell disease pathogenesis, pulmonary hypertension, and mortality.
Plasma amino acid levels, plasma and erythrocyte arginase activities, and pulmonary hypertension status as measured by Doppler echocardiogram were prospectively obtained in outpatients with sickle cell disease. Patients were followed up for survival up to 49 months.
Urban tertiary care center and community clinics in the United States between February 2001 and March 2005.
Two hundred twenty-eight patients with sickle cell disease, aged 18 to 74 years, and 36 control participants.
Plasma amino acid levels, plasma and erythrocyte arginase activities, diagnosis of pulmonary hypertension, and mortality.
Plasma arginase activity was significantly elevated in patients with sickle cell disease, with highest activity found in patients with secondary pulmonary hypertension. Arginase activity correlated with the arginine-ornithine ratio, and lower ratios were associated with greater severity of pulmonary hypertension and with mortality in this population (risk ratio, 2.5; 95% confidence interval [CI], 1.2-5.2; P = .006). Global arginine bioavailability, characterized by the ratio of arginine to ornithine plus citrulline, was also strongly associated with mortality (risk ratio, 3.6; 95% CI, 1.5-8.3; P<.001). Increased plasma arginase activity was correlated with increased intravascular hemolytic rate and, to a lesser extent, with markers of inflammation and soluble adhesion molecule levels.
These data support a novel mechanism of disease in which hemolysis contributes to reduced nitric oxide bioavailability and endothelial dysfunction via release of erythrocyte arginase, which limits arginine bioavailability, and release of erythrocyte hemoglobin, which scavenges nitric oxide. The ratios of arginine to ornithine and arginine to ornithine plus citrulline are independently associated with pulmonary hypertension and increased mortality in patients with sickle cell disease.

Download full-text


Available from: Gregory James Kato,
  • Source
    • "Both isoforms, however, have been found in vascular tissue (Bachetti et al., 2004; Berkowitz et al., 2003). Elevated arginase activity has been associated with cardiovascular pathologies such as hypertension, diabetes, atherosclerosis, ischemic reperfusion injury, erectile dysfunction and sickle cell anemia (Bagnost et al., 2008; Bivalacqua et al., 2007; Jeyabalan et al., 2008; Morris et al., 2005; Romero et al., 2008). In these conditions, elevation of arginase has been shown to mediate vascular dysfunction through limiting nitric oxide (NO) production or availability. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Enhanced vascular arginase activity can impair endothelium-dependent vasorelaxation by decreasing l-arginine availability to endothelial nitric oxide (NO) synthase, thereby reducing NO production and uncoupling NOS function. Elevated angiotensin II (Ang II) is a key component of endothelial dysfunction in many cardiovascular diseases and has been linked to elevated arginase activity. In this study we explored the signaling pathway leading to increased arginase expression/activity in response to Ang II in bovine aortic endothelial cells (BAEC). Our previous studies indicate involvement of p38 mitogen activated protein kinase (MAPK) in Ang II-induced arginase upregulation and reduced NO production. In this study, we further investigated the Ang II-transcriptional regulation of arginase 1 in endothelial cells. Our results indicate the involvement of ATF-2 transcription factor of the AP1 family in arginase 1 upregulation and in limiting NO production. Using small interfering RNA (siRNA) targeting ATF-2, we showed that this transcription factor is required for Ang II-induced arginase 1 gene upregulation and increased arginase 1 expression and activity, leading to reduced NO production. Electrophoretic mobility shift assay and chromatin immunoprecipitation assay further confirmed the involvement of ATF-2. Moreover, our data indicate that p38 MAPK phosphorylates ATF-2 in response to Ang II. Collectively, our results indicate that Ang II increases endothelial arginase activity/expression through a p38 MAPK/ATF-2 pathway leading to reduced endothelial NO production. These signaling steps might be therapeutic targets for preventing vascular endothelial dysfunction associated with elevated arginase activity/expression. Copyright © 2014 Elsevier B.V. All rights reserved.
    European Journal of Pharmacology 10/2014; 746C:106-114. DOI:10.1016/j.ejphar.2014.10.042 · 2.53 Impact Factor
  • Source
    • "NO metabolism is very important in sickle cell disease. We, and others have shown that it is dysregulated [17], [44], and the measurement of exhaled NO has been used in clinical studies in sickle cell disease [24]. Both decreased hematocrit and increased free plasma hemoglobin have been described to contribute to the vaso-occlusive events found in SCD, leading to painful episodes and possible organ damage [44], [45]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nitric oxide (NO) is a key regulator of vascular tone. Endothelial nitric oxide synthase (eNOS) is responsible for NO generation under normoxic conditions. Under hypoxia however, eNOS is inactive and red blood cells (RBC) provide an alternative NO generation pathway from nitrite to regulate hypoxic vasodilation. While nitrite reductase activity of hemoglobin is well acknowledged, little is known about generation of NO by intact RBC with physiological hemoglobin concentrations. We aimed to develop and apply a new approach to provide insights in the ability of RBC to convert nitrite into NO under hypoxic conditions. We established a novel experimental setup to evaluate nitrite uptake and the release of NO from RBC into the gas-phase under different conditions. NO measurements were similar to well-established clinical measurements of exhaled NO. Nitrite uptake was rapid, and after an initial lag phase NO release from RBC was constant in time under hypoxic conditions. The presence of oxygen greatly reduced NO release, whereas inhibition of eNOS and xanthine oxidoreductase (XOR) did not affect NO release. A decreased pH increased NO release under hypoxic conditions. Hypothermia lowered NO release, while hyperthermia increased NO release. Whereas fetal hemoglobin did not alter NO release compared to adult hemoglobin, sickle RBC showed an increased ability to release NO. Under all conditions nitrite uptake by RBC was similar. This study shows that nitrite uptake into RBC is rapid and release of NO into the gas-phase continues for prolonged periods of time under hypoxic conditions. Changes in the RBC environment such as pH, temperature or hemoglobin type, affect NO release.
    PLoS ONE 07/2014; 9(7):e101626. DOI:10.1371/journal.pone.0101626 · 3.23 Impact Factor
  • Source
    • "We simultaneously measured Arg, ADMA, SDMA, MMA, Cit, and Orn by liquid chromatography-tandem mass spectrometry (LC-MS/MS) [39]. The ratio Arg/(Orn + Cit), as index of global Arg availability [40] [41], and the ratio Orn/Cit, as indicator of the relative activity of arginase and NOS [19], were computed. All the determinations were performed both in plasma and in lysed RBCs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: A decreased nitric oxide (NO) bioavailability and an increased oxidative stress play a pivotal role in different cardiovascular pathologies. As red blood cells (RBCs) participate in NO formation in the bloodstream, the aim of this study was to outline the metabolic profile of L-arginine (Arg)/NO pathway and of oxidative stress status in RBCs and in plasma of patients with microvascular angina (MVA), investigating similarities and differences with respect to coronary artery disease (CAD) patients or healthy controls (Ctrl). Analytes involved in Arg/NO pathway and the ratio of oxidized and reduced forms of glutathione were measured by LC-MS/MS. The arginase and the NO synthase (NOS) expression were evaluated by immunofluorescence staining. RBCs from MVA patients show increased levels of NO synthesis inhibitors, parallel to that found in plasma, and a reduction of NO synthase expression. When summary scores were computed, both patient groups were associated with a positive oxidative score and a negative NO score, with the CAD group located in a more extreme position with respect to Ctrl. This finding points out to an impairment of the capacity of RBCs to produce NO in a pathological condition characterized mostly by alterations at the microvascular bed with no significant coronary stenosis.
    Oxidative medicine and cellular longevity 04/2014; 2014(2):726539. DOI:10.1155/2014/726539 · 3.36 Impact Factor
Show more